BlackRock Investment Management’s Aldeyra Therapeutics ALDX Stock Holding History

BlackRock Investment Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$8K	Hold	1,457	–	–	﹤0.01%	3649
2016 Q3	$11K	Hold	1,457	–	–	﹤0.01%	3554
2016 Q2	$8K	Buy	1,457 +499	+52%	+$2.79K	﹤0.01%	3703
2016 Q1	$4K	Hold	958	–	–	﹤0.01%	3850
2015 Q4	$6K	Hold	958	–	–	﹤0.01%	3815
2015 Q3	$6K	Hold	958	–	–	﹤0.01%	3860
2015 Q2	$7K	Buy	958 +689	+256%	+$5.94K	﹤0.01%	3844
2015 Q1	$3K	Hold	269	–	–	﹤0.01%	3930
2014 Q4	$2K	Hold	269	–	–	﹤0.01%	4044
2014 Q3	$2K	Hold	269	–	–	﹤0.01%	4001
2014 Q2	$2K	Buy	+269	New	+$1.81K	﹤0.01%	3992

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Investment Management's ALDX Position: Q4 2016 in Review

BlackRock Investment Management held its Aldeyra Therapeutics (ALDX) position steady in Q4 2016 at 1,457 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #3649.

BlackRock Investment Management first reported a position in ALDX in Q2 2014 and has held it in 11 quarters since. The position peaked at $11K in Q3 2016. 20 funds tracked by Wall St. Rank hold ALDX as of Q4 2016.

BlackRock Investment Management held 1,457 shares of Aldeyra Therapeutics worth $8K as of Q4 2016.
BlackRock Investment Management left its Aldeyra Therapeutics share count unchanged in Q4 2016.
Aldeyra Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3649 holding.
BlackRock Investment Management first reported a position in Aldeyra Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Aldeyra Therapeutics position peaked at $11K in Q3 2016.
20 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.